Vertex Pharmaceuticals Incorporated
VRTXHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeVertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. Valued at $113.59B, VRTX is a large-cap name in its sector. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Market Cap
$113.59B
Beta
0.30
P/E (TTM)
26.53
P/E (Fwd)
20.84
EPS (TTM)
$16.87
EPS (Fwd)
$21.47
ROE
24.2%
ROA
12.1%
Cash
$7.25B
Total Debt
$1.99B
Free CF
$2.78B
52W Change
0.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $7.25B in cash comfortably exceeding the $1.99B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $2.78B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 24.2%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 12.1% further supports the picture of efficient asset utilization. Revenue has grown from $8.93B (2022) to $12.00B (2025), reflecting a 34% increase over the period.
With a beta below 0.7, Vertex Pharmaceuticals Incorporated typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, VRTX has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VRTX.